286 related articles for article (PubMed ID: 18227600)
1. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
Khan MK; Thukral SS; Gaind R
Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
[TBL] [Abstract][Full Text] [Related]
2. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam.
Kaur J; Mahajan G; Chand K; Sheevani ; Chopra S
J Clin Diagn Res; 2016 Jan; 10(1):DC05-8. PubMed ID: 26894064
[TBL] [Abstract][Full Text] [Related]
4. AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
Gupta V; Kumarasamy K; Gulati N; Garg R; Krishnan P; Chander J
Indian J Med Res; 2012 Aug; 136(2):237-41. PubMed ID: 22960890
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended spectrum beta-lactamases.
Manchanda V; Singh NP; Goyal R; Kumar A; Thukral SS
Indian J Med Res; 2005 Oct; 122(4):330-7. PubMed ID: 16394326
[TBL] [Abstract][Full Text] [Related]
6. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis.
Datta P; Gupta V; Arora S; Garg S; Chander J
Jpn J Infect Dis; 2014; 67(1):44-6. PubMed ID: 24451101
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli.
Elawady BA; Mahmoud NR; Badawi HE; Badr AEE; Gohar NM
BMC Infect Dis; 2024 Apr; 24(1):434. PubMed ID: 38654148
[TBL] [Abstract][Full Text] [Related]
10. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extended-spectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis.
Song W; Jeong SH; Kim JS; Kim HS; Shin DH; Roh KH; Lee KM
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):315-8. PubMed ID: 17174510
[TBL] [Abstract][Full Text] [Related]
11. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods.
Steward CD; Rasheed JK; Hubert SK; Biddle JW; Raney PM; Anderson GJ; Williams PP; Brittain KL; Oliver A; McGowan JE; Tenover FC
J Clin Microbiol; 2001 Aug; 39(8):2864-72. PubMed ID: 11474005
[TBL] [Abstract][Full Text] [Related]
12. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
[TBL] [Abstract][Full Text] [Related]
13. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
[TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
[TBL] [Abstract][Full Text] [Related]
17. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
20. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
